Skip to main content
Midas Edge

Neuronetics Inc

For the period ended Dec 31, 2023. Filed Mar 8, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 8, 2024

STIM$2.18+1.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Changes in Stockholders’ Equity

(In thousands)

​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Additional · Total
​ · ​ · Common Stock · ​ · Paid-in · ​ · Accumulated · ​ · Stockholders’
​ · Shares · Amount · Capital · Deficit · Equity
Balance at December 31, 202019,114​$191​$302,842​$(277,540)​$25,493
Share-based awards and options exercises1,715​17​2,418​—​2,435
Issuance of common stock, net of issuance costs of $401​5,566​56​80,515​—​80,571
Share-based compensation expense—​—​7,869​—​7,869
Net loss—​—​—​(31,193)​(31,193)
Balance at December 31, 202126,395​264​393,644​(308,733)​85,175
Share-based awards and options exercises873​9​289​—​298
Share-based compensation expense—​—​8,746​—​8,746
Net loss—​—​—​(37,159)​(37,159)
Balance at December 31, 202227,268​273​402,679​(345,892)​57,060
Share-based awards and options exercises1,824​18​(18)​—​—
Share-based compensation expense—​—​7,319​—​7,319
Net loss—​—​—​(30,189)​(30,189)
Balance at December 31, 202329,092​$291​$409,980​$(376,081)​$34,190
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.